Skip Navigation

European Heart Journal 2004 25(3):188-189; doi:10.1016/j.ehj.2003.10.014
Copyright © 2004 by the European Society of Cardiology.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in EHJ
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (5)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Billinger, M
Right arrow Articles by Meier, B
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Billinger, M
Right arrow Articles by Meier, B
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Editorial

Prevention of contrast-induced renal dysfunction by N-acetylcysteine

Truth or myth?

M Billinger, O.M Hess and B Meier*

Swiss Cardiovascular Center Bern, Cardiology, University Hospital, 3010 Bern, Switzerland

* Corresponding author: Tel.: +41-31-632-3077; Fax: +41-31-382-1069
E-mail address: bernhard.meier@insel.ch

Received 13 October 2003; accepted 16 October 2003

The first 10% of the full text of this article appears below.

See doi:10.1016/j.ehj.2003.11.016 and doi:10.1016/j.ehj.2003.11.011for the articles to which this editorial refers

There is an increase in the use of radiographic contrast agents in cardiovascular medicine for diagnostic and therapeutic interventions. However, these interventions are becoming more and more popular in elderly and polymorbide patients, thereby increasing the risk of contrast-induced complications such as renal dysfunction and delayed allergic reactions. A particular risk for renal dysfunction has been attributed to pre-existing renal dysfunction, diabetic nephropathy, dehydration, druginteractions and the use of . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in EHJ:

Oral acetylcysteine as an adjunct to saline hydration for the prevention of contrast-induced nephropathy following coronary angiography: A randomized controlled trial and review of the current literature
Ilan Goldenberg, Michael Shechter, Shlomi Matetzky, Michael Jonas, Miriam Adam, Hanna Pres, Dan Elian, Oren Agranat, Ehud Schwammenthal, and Victor Guetta
EHJ 2004 25: 212-218. [Abstract] [Full Text]  



This article has been cited by other articles:


Home page
 J Am Coll CardiolHome page
A. Recio-Mayoral, M. Chaparro, B. Prado, R. Cozar, I. Mendez, D. Banerjee, J. C. Kaski, J. Cubero, and J. M. Cruz
The Reno-Protective Effect of Hydration With Sodium Bicarbonate Plus N-Acetylcysteine in Patients Undergoing Emergency Percutaneous Coronary Intervention: The RENO Study
J. Am. Coll. Cardiol., March 27, 2007; 49(12): 1283 - 1288.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
M. Maeder, M. Klein, T. Fehr, and H. Rickli
Contrast nephropathy: Review focusing on prevention
J. Am. Coll. Cardiol., November 2, 2004; 44(9): 1763 - 1771.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
P. Nicol and C. Axelson
Contrast agent nephropathy
Eur. Heart J., August 1, 2004; 25(15): 1369 - 1369.
[Full Text] [PDF]